Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- October 1, 2022
has subject area
- Atherosclerosis (MeSH)
- Diabetes Mellitus, Type 2 (MeSH)
- Glucagon-Like Peptides (MeSH)
- Glycated Hemoglobin (MeSH)
- Humans (MeSH)
- Hypoglycemic Agents (MeSH)
- Immunoglobulin Fc Fragments (MeSH)
- Recombinant Fusion Proteins (MeSH)
- Treatment Outcome (MeSH)
published in
- Diabetes Reviews Journal